Sheffer, Michal
Lowry, Emily http://orcid.org/0000-0003-1036-779X
Beelen, Nicky
Borah, Minasri
Amara, Suha Naffar-Abu
Mader, Chris C.
Roth, Jennifer A.
Tsherniak, Aviad http://orcid.org/0000-0002-3797-1877
Freeman, Samuel S. http://orcid.org/0000-0001-8285-0057
Dashevsky, Olga
Gandolfi, Sara
Bender, Samantha
Bryan, Jordan G. http://orcid.org/0000-0002-4984-0516
Zhu, Cong
Wang, Li
Tariq, Ifrah http://orcid.org/0000-0003-0684-8769
Kamath, Govinda M.
Simoes, Ricardo De Matos
Dhimolea, Eugen
Yu, Channing http://orcid.org/0000-0002-3231-2565
Hu, Yiguo http://orcid.org/0000-0002-3973-2140
Dufva, Olli http://orcid.org/0000-0002-8084-0282
Giannakis, Marios
Syrgkanis, Vasilis
Fraenkel, Ernest http://orcid.org/0000-0001-9249-8181
Golub, Todd http://orcid.org/0000-0003-0113-2403
Romee, Rizwan
Mustjoki, Satu http://orcid.org/0000-0002-0816-8241
Culhane, Aedin C. http://orcid.org/0000-0002-1395-9734
Wieten, Lotte http://orcid.org/0000-0002-4503-1623
Mitsiades, Constantine S.
Article History
Received: 3 April 2020
Accepted: 18 May 2021
First Online: 12 July 2021
Competing interests
: C.C.M., J.A.R., C.Y., T.G., L. Wieten, M.S. and C.S.M. are authors of a patent application related to antitumor activity of NK cells. C.S.M. also discloses consultant/honoraria from Fate Therapeutics, Ionis Pharmaceuticals and FIMECS; employment of a relative with Takeda; and research funding from Janssen/Johnson & Johnson, TEVA, EMD Serono, Abbvie, Arch Oncology, Karyopharm, Sanofi, Nurix and H3 Biomedicine. M.G. receives research funding from Bristol-Myers Squibb and Merck. A.T. is a consultant for Tango Therapeutics. S.M. has received honoraria and research funding from Novartis, Pfizer and Bristol-Myers Squibb (not related to this study). The remaining authors declare no competing interests.